You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 164 No. 4, February 23, 2004 TABLE OF CONTENTS
  Archives
  •  Online Features
  Review Article
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (84)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Thrombolysis
 •Cardiovascular System
 •Review
 •Adverse Effects
 •Coagulation Disorders
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Treatment of Heparin-Induced Thrombocytopenia

A Critical Review

Jack Hirsh, MD, FRCPC, FRACP, FRSC, DSc; Nancy Heddle, MSc; John G. Kelton, MD

Arch Intern Med. 2004;164:361-369.

Heparin-induced thrombocytopenia (HIT) is a serious complication of heparin therapy that has a high rate of morbidity (thrombosis and amputation) and mortality. In the past, a number of different anticoagulants have been used to treat HIT in an attempt to prevent these complications. More recently, direct thrombin inhibitors have become popular. This systematic review summarizes the risk for thrombosis in HIT patients when heparin therapy is stopped; evidence of the efficacy of thrombin inhibitors in patients with HIT with and without thrombosis; evidence supporting the use of thrombin inhibitors in patients with a history of HIT who require a coronary intervention procedure; and the risk for bleeding when antithrombotic agents are used.


From the Henderson Research Centre, Henderson Hospital (Dr Hirsh), and the Department of Medicine, McMaster University (Drs Hirsh and Kelton and Ms Heddle), Hamilton, Ontario. Dr Kelton has acted as a consultant to GlaxoSmithKline.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Heparin-Induced Thrombocytopenia: A Contemporary Clinical Approach to Diagnosis and Management
Shantsila et al.
Chest 2009;135:1651-1664.
ABSTRACT | FULL TEXT  

Heparin-induced Thrombocytopenia: Pathophysiology, Diagnosis, and Review of Pharmacotherapy
Kanaan and Al-Homsi
Journal of Pharmacy Practice 2009;22:149-157.
ABSTRACT  

Heparin-induced thrombocytopenia: a historical perspective
Kelton and Warkentin
Blood 2008;112:2607-2616.
FULL TEXT  

Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC)
Authors/Task Force Members et al.
Eur Heart J 2008;29:2276-2315.
FULL TEXT  

Argatroban Anticoagulation in Intensive Care Patients: Effects of Heart Failure and Multiple Organ System Failure
Begelman et al.
J Intensive Care Med 2008;23:313-320.
ABSTRACT  

Reduced Argatroban Doses After Coronary Artery Bypass Graft Surgery
Hoffman et al.
The Annals of Pharmacotherapy 2008;42:309-316.
ABSTRACT | FULL TEXT  

Argatroban Therapy for Heparin-Induced Thrombocytopenia in Acutely Ill Patients
Gray et al.
CLIN APPL THROMB HEMOST 2007;13:353-361.
ABSTRACT  

Reducing Thrombotic Complications in the Perioperative Setting: An Update on Heparin-Induced Thrombocytopenia
Levy et al.
Anesth. Analg. 2007;105:570-582.
ABSTRACT | FULL TEXT  

Argatroban Anticoagulation in Obese Versus Nonobese Patients: Implications for Treating Heparin-induced Thrombocytopenia
Rice et al.
J Clin Pharmacol 2007;47:1028-1034.
FULL TEXT  

Continuous Renal Replacement Therapy in the Adult Intensive Care Unit: History and Current Trends
Dirkes and Hodge
Crit Care Nurse 2007;27:61-80.
FULL TEXT  

Bilateral Lower Extremity Gangrene Requiring Amputation Associated With Heparin-Induced Thrombocytopenia: A Case Report
Dickinson and Lawrence
ANGIOLOGY 2007;58:234-237.
ABSTRACT  

Review: New anticoagulants: a story of promise and disappointment
Watson and Greaves
British Journal of Diabetes & Vascular Disease 2007;7:51-58.
ABSTRACT  

Prevalence of Heparin/Platelet Factor 4 Antibodies Before and After Cardiac Surgery
Everett et al.
Ann. Thorac. Surg. 2007;83:592-597.
ABSTRACT | FULL TEXT  

Heparin-Induced Thrombocytopenia in a Case of Endovascular Aneurysm Coiling
Gupta et al.
Am. J. Neuroradiol. 2007;28:155-158.
ABSTRACT | FULL TEXT  

Heparin-induced thrombocytopenia: advances in diagnosis and treatment.
Cooney
Crit Care Nurse 2006;26:30-36.
FULL TEXT  

How frequently is venous thromboembolism in heparin-treated patients associated with heparin-induced thrombocytopenia?
Levine et al.
Chest 2006;130:681-687.
ABSTRACT | FULL TEXT  

Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin
Tardy et al.
Blood 2006;108:1492-1496.
ABSTRACT | FULL TEXT  

Thromboembolism in Cancer Patients: Pathogenesis and Treatment
Adess et al.
CLIN APPL THROMB HEMOST 2006;12:254-266.
ABSTRACT  

Fondaparinux for Thromboembolic Treatment and Prophylaxis of Heparin-Induced Thrombocytopenia
Efird and Kockler
The Annals of Pharmacotherapy 2006;40:1383-1387.
ABSTRACT | FULL TEXT  

Effects of Argatroban Therapy, Demographic Variables, and Platelet Count on Thrombotic Risks in Heparin-Induced Thrombocytopenia
Lewis et al.
Chest 2006;129:1407-1416.
ABSTRACT | FULL TEXT  

Argatroban Therapy in Heparin-Induced Thrombocytopenia With Hepatic Dysfunction
Levine et al.
Chest 2006;129:1167-1175.
ABSTRACT | FULL TEXT  

Argatroban for Suspected Heparin-Induced Thrombocytopenia: Contemporary Experience at a Large Teaching Hospital
Kodityal et al.
J Intensive Care Med 2006;21:86-92.
ABSTRACT  

Bilateral Lower Extremity Gangrene Requiring Amputation Associated with Heparin-Induced Thrombocytopenia: A Case Report
Dickinson et al.
VASC ENDOVASCULAR SURG 2006;40:161-164.
ABSTRACT  

Argatroban and Lepirudin: Clinical Trials to Clinical Practice
Messmore et al.
CLIN APPL THROMB HEMOST 2005;11:367-369.
 

Transitioning from Argatroban to Warfarin Therapy in Patients with Heparin-induced Thrombocytopenia
Hursting et al.
CLIN APPL THROMB HEMOST 2005;11:279-287.
ABSTRACT  

When Heparins Promote Thrombosis: Review of Heparin-Induced Thrombocytopenia
Jang and Hursting
Circulation 2005;111:2671-2683.
FULL TEXT  

Direct thrombin inhibitors in heparin-induced thrombocytopenia
Verme-Gibboney et al.
Am J Health Syst Pharm 2005;62:247-250.
FULL TEXT  

The Pathophysiology of Heparin-Induced Thrombocytopenia: Biological Basis for Treatment
Kelton
Chest 2005;127:9S-20S.
FULL TEXT  

Argatroban and Renal Replacement Therapy in Patients with Heparin-Induced Thrombocytopenia
Tang et al.
The Annals of Pharmacotherapy 2005;39:231-236.
ABSTRACT | FULL TEXT  

Congenital and Acquired Thrombocytopenia
Cines et al.
ASH Education Book 2004;2004:390-406.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2004 American Medical Association. All Rights Reserved.